1.1
Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:
-
they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
-
the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.